Experience with rituximab therapy in a real-life sample of multiple sclerosis patients
ConclusionsOur real-life experience confirms that off-label therapy with RTX may represent a valid, cost-effective therapeutic option in MS.
Source: Neurological Sciences - Category: Neurology Source Type: research
More News: Autoimmune Disease | Brain | Disability | Multiple Sclerosis | Neurology | Rituxan | Study